BzODZ-EPyr
 | |
| Systematic (IUPAC) name | |
|---|---|
|
3-benzyl-5-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1,2,4-oxadiazole | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem | CID 9842447 |
| Chemical data | |
| Formula | C23H24N4O |
| Molar mass | 372.47 g·mol−1 |
| |
| |
BzODZ-EPyr is an indole based synthetic cannabinoid that has been sold as a designer drug in Russia.[1]
It acts as a CB1 receptor agonist with a pKB value of 7.2 and demonstrates that replacing the ketone in 3-carbonylindoles with an oxadiazole spacer does generally not lead to activity loss.[2][3]
See also
References
- ↑ Vadim Shevyrin, Vladimir Melkozerov, Oleg Eltsov, Yuri Shafran, Yuri Morzherin (December 2015). "Synthetic cannabinoid 3-benzyl-5-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1,2,4-oxadiazole. The first detection in illicit market of new psychoactive substances". Forensic Science International. doi:10.1016/j.forsciint.2015.12.019. PMID 26771874.
- ↑ Gerard P. Moloney, James A. Angus, Alan D. Robertson, Martin J. Stoermer, Michael Robinson, Christine E. Wright, Ken McRae, Arthur Christopoulos (March 2008). "Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: Novel agonists for the CB1 receptor". European Journal of Medicinal Chemistry 43 (3): 513–539. doi:10.1016/j.ejmech.2007.04.007. PMID 17582659.
- ↑ Peter Gerard Moloney, Alan Duncan Robertson (2004). "Patent Application EP1339710 - 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives".
This article is issued from Wikipedia - version of the Monday, April 11, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.